CRSP CRISPR Therapeutics AG - Common Shares
$52,78
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 3, 2026
Rango 52S
$44–$78
25% of range
Calificación del Analista
HOLD
29 analysts
Precio Objetivo
$88
+66% upside
P/E (TTM)
-8.2
ROE
-32.0%
Margen de Beneficio Neto
-16569.8%
Acerca de CRISPR Therapeutics AG - Common Shares Descripción general de la empresa de Wikipedia
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Leer más
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
CRSP Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$52.77
Capitalización Bursátil
$5.06B
P/E (TTM)
-8.2
BPA (TTM)
$-6.47
Ingresos (TTM)
$4M
Rendimiento div.
—
ROE
-32.0%
Deuda/Capital
—
Rango 52S
$44 – $78
CRSP Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$4M
2016-12-31
→
2025-12-31
BPA
$-6.47
2017-12-31
→
2025-12-31
Flujo de caja libre
$-346M
2016-12-31
→
2025-12-31
Márgenes
-16569.8%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
CRSP
Mediana de Pares
P/E (TTM)
-8.2
—
P/S (TTM) (P/V (TTM))
1441.8
56.3
P/B (P/C)
2.6
3.0
Price / FCF (Precio / FCF)
-14.6
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
CRSP
Mediana de Pares
Operating Margin (Margen Operativo)
-18933.7%
—
Net Profit Margin (Margen de Beneficio Neto)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
CRSP
Mediana de Pares
Current Ratio (Ratio corriente)
13.3
6.7
Quick Ratio (Ratio Rápido)
13.2
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
CRSP
Mediana de Pares
Revenue YoY (Ingresos interanuales)
-90.6%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
43.1%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
37.3%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
CRSP
Mediana de Pares
CRSP Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
29 analistas
- Compra fuerte 6 20,7%
- Compra 11 37,9%
- Mantener 12 41,4%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
18 analistas · 2026-08-15
Mediana
$80.00
Ahora
$52.77
Mín
$44.00
Máx
$291.00
Objetivo mediano
$80.00
+51,6%
Objetivo medio
$87.56
+65,9%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
0.01%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.94 | $-1.22 | 0.28% |
| 31 de marzo de 2026 | $-1.28 | $-1.25 | -0.03% |
| 31 de diciembre de 2025 | $-1.37 | $-1.18 | -0.19% |
| 30 de septiembre de 2025 | $-1.17 | $-1.29 | 0.12% |
| 30 de junio de 2025 | $-1.29 | $-1.45 | 0.16% |
| 31 de marzo de 2025 | $-1.58 | $-1.28 | -0.30% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 15
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
Balance general 25
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
Flujo de Efectivo 14
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
Liquidez y Solvencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
Eficiencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
Estado de resultados 14
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
Balance general 25
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
Flujo de Efectivo 11
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
Rentabilidad 7
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
Liquidez y Solvencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
Eficiencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
Valoración (TTM) 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $4M | $37M | $371M | $1M | $915M |
| Margen Operativo % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Beneficio neto | $-582M | $-366M | $-154M | $-650M | $378M |
| EPS Diluido | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| Ratio Rápido | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-346M | $-145M | $-270M | $-533M | $457M |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- La acción de CRISPR Therapeutics está absurdamente barata -- He aquí por qué los Analysts ven un 437% de Upside Potential
- ¿Liderazgo de Crecimiento Mega-Cap o Potencial de Crecimiento de Pequeña Capitalización? VUG vs. VBK
- 1 El analista principal de Wall Street cree que CRISPR Therapeutics podría duplicarse con creces. ¿Debería comprar las acciones a toda prisa?
- Salida de ETF Notable Detectada - ARKK, CRSP, TEM, HOOD
- Esta Biotecnología Tiene una Cartera de Productos que Podría Redefinir Toda su Área Terapéutica
- Cathie Wood Busca Ofertas: 2 Acciones Que Acaba de Comprar
- ¿Es Esta Acción de Biotecnología Tu Mejor Oportunidad Para Construir una Posición Que Te Haga Millonario?
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 573 declarantes · $3.3B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 89 (0 vs trimestre anterior) | 47 (-13 vs trimestre anterior) | 148 (-24 vs trimestre anterior) | 145 (+21 vs trimestre anterior) | +5.4M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| ARK Investment Management LLC | $515 999 631 | 9 460 939 | 15,58% | Acciones |
| Orbis Allan Gray Ltd | $296 334 582 | 5 433 344 | 8,95% | Acciones |
| Capital World Investors | $259 039 094 | 4 749 525 | 7,82% | Acciones |
| STATE STREET CORP | $235 703 664 | 4 321 666 | 7,12% | Acciones |
| GSK plc | $175 652 997 | 3 220 627 | 5,30% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $117 453 717 | 2 153 015 | 3,55% | Acciones |
| SR One Capital Management, LP | $111 194 134 | 2 038 763 | 3,36% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $108 459 389 | 1 988 621 | 3,27% | Acciones |
| Sumitomo Mitsui Trust Group, Inc. | $93 848 832 | 1 720 734 | 2,83% | Acciones |
| Amova Asset Management Americas, Inc. | $93 762 487 | 1 720 097 | 2,83% | Acciones |
| EcoR1 Capital, LLC | $75 771 113 | 1 389 276 | 2,29% | Acciones |
| Capital International Investors | $69 178 918 | 1 268 407 | 2,09% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $64 457 935 | 1 181 847 | 1,95% | Acciones |
| NEA Management Company, LLC | $57 734 408 | 1 058 570 | 1,74% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57 694 430 | 1 057 837 | 1,74% | Acciones |
| FMR LLC | $53 577 751 | 982 357 | 1,62% | Acciones |
| D. E. Shaw & Co., Inc. | $48 748 506 | 893 812 | 1,47% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35 380 807 | 648 713 | 1,07% | Acciones |
| UBS Group AG | $32 419 612 | 594 419 | 0,98% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $31 089 982 | 570 040 | 0,94% | Acciones |
| VANGUARD GROUP INC | $27 714 225 | 528 494 | 0,84% | Acciones |
| CITADEL ADVISORS LLC | $25 404 514 | 465 796 | 0,77% | Acciones |
| BANK OF AMERICA CORP /DE/ | $23 509 740 | 431 055 | 0,71% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23 298 288 | 427 178 | 0,70% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $20 836 025 | 382 032 | 0,63% | Acciones |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20 833 789 | 381 991 | 0,63% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18 456 336 | 338 400 | 0,56% | Opción de venta |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17 763 678 | 325 700 | 0,54% | Opción de compra |
| Logos Global Management LP | $16 362 000 | 300 000 | 0,49% | Acciones |
| CITADEL ADVISORS LLC | $15 822 054 | 290 100 | 0,48% | Opción de venta |
| Squarepoint Ops LLC | $15 641 472 | 286 789 | 0,47% | Acciones |
| NORGES BANK | $14 767 032 | 270 756 | 0,45% | Acciones |
| CITADEL ADVISORS LLC | $13 973 148 | 256 200 | 0,42% | Opción de compra |
| GOLDMAN SACHS GROUP INC | $12 748 193 | 233 740 | 0,38% | Acciones |
| JANE STREET GROUP, LLC | $12 566 016 | 230 400 | 0,38% | Opción de compra |
| PEAK6 LLC | $11 633 382 | 213 300 | 0,35% | Opción de venta |
| Swiss National Bank | $9 228 168 | 169 200 | 0,28% | Acciones |
| Susquehanna Portfolio Strategies, LLC | $8 945 978 | 164 026 | 0,27% | Acciones |
| TWO SIGMA ADVISERS, LP | $8 516 256 | 162 400 | 0,26% | Acciones |
| LPL Financial LLC | $8 376 280 | 153 581 | 0,25% | Acciones |
| Bank of New York Mellon Corp | $8 337 366 | 152 867 | 0,25% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $8 301 261 | 152 205 | 0,25% | Acciones |
| Versant Venture Management, LLC | $8 117 243 | 148 831 | 0,25% | Acciones |
| Pictet Asset Management Holding SA | $7 989 776 | 142 213 | 0,24% | Acciones |
| Life Cycle Investment Partners Ltd | $7 836 962 | 143 692 | 0,24% | Acciones |
| TD Asset Management Inc | $7 777 513 | 142 602 | 0,23% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $7 606 257 | 139 462 | 0,23% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $7 230 750 | 132 577 | 0,22% | Acciones |
| RHUMBLINE ADVISERS | $6 627 197 | 121 511 | 0,20% | Acciones |
| SFE Investment Counsel | $6 229 434 | 16 700 | 0,19% | Opción de venta |
| Private Advisor Group, LLC | $6 060 980 | 111 129 | 0,18% | Acciones |
| EverSource Wealth Advisors, LLC | $6 032 669 | 110 610 | 0,18% | Acciones |
| CONGRESS ASSET MANAGEMENT CO | $5 969 567 | 109 453 | 0,18% | Acciones |
| BlackRock, Inc. | $5 937 061 | 108 857 | 0,18% | Acciones |
| D. E. Shaw & Co., Inc. | $5 901 228 | 108 200 | 0,18% | Opción de compra |
| Campbell & CO Investment Adviser LLC | $5 864 632 | 107 529 | 0,18% | Acciones |
| JANE STREET GROUP, LLC | $5 852 142 | 107 300 | 0,18% | Opción de venta |
| California Public Employees Retirement System | $5 599 567 | 102 669 | 0,17% | Acciones |
| CAPITAL INTERNATIONAL SARL | $5 521 521 | 101 238 | 0,17% | Acciones |
| Affinity Asset Advisors, LLC | $5 454 000 | 100 000 | 0,16% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $5 439 011 | 114 337 | 0,16% | Acciones |
| CLOUGH CAPITAL PARTNERS L P | $5 363 300 | 98 337 | 0,16% | Acciones |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5 172 465 | 94 838 | 0,16% | Acciones |
| Slow Capital, Inc. | $5 066 439 | 92 894 | 0,15% | Acciones |
| CAPITAL FUND MANAGEMENT S.A. | $4 867 258 | 89 242 | 0,15% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4 815 606 | 101 232 | 0,15% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $4 720 437 | 86 550 | 0,14% | Acciones |
| GROUP ONE TRADING LLC | $4 638 082 | 85 040 | 0,14% | Acciones |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4 575 742 | 83 897 | 0,14% | Acciones |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4 502 113 | 82 547 | 0,14% | Acciones |
| Concurrent Investment Advisors, LLC | $4 497 728 | 82 467 | 0,14% | Acciones |
| WELLS FARGO & COMPANY/MN | $4 309 151 | 79 009 | 0,13% | Acciones |
| Fisher Asset Management, LLC | $4 251 957 | 77 960 | 0,13% | Acciones |
| Trexquant Investment LP | $4 225 268 | 77 471 | 0,13% | Acciones |
| COMMONWEALTH EQUITY SERVICES, LLC | $4 194 122 | 76 900 | 0,13% | Acciones |
| JONES FINANCIAL COMPANIES LLLP | $4 055 652 | 73 847 | 0,12% | Acciones |
| Man Group plc | $3 992 001 | 73 194 | 0,12% | Acciones |
| PEAK6 LLC | $3 834 162 | 70 300 | 0,12% | Opción de compra |
| ENVESTNET ASSET MANAGEMENT INC | $3 822 196 | 70 081 | 0,12% | Acciones |
| ALGERT GLOBAL LLC | $3 593 095 | 65 880 | 0,11% | Acciones |
| Walleye Trading LLC | $3 528 738 | 64 700 | 0,11% | Opción de venta |
| MILLENNIUM MANAGEMENT LLC | $3 146 958 | 57 700 | 0,10% | Opción de compra |
| CAPITAL INTERNATIONAL LTD /CA/ | $3 057 840 | 56 066 | 0,09% | Acciones |
| NOMURA HOLDINGS INC | $3 055 713 | 56 027 | 0,09% | Acciones |
| Rafferty Asset Management, LLC | $3 045 132 | 55 833 | 0,09% | Acciones |
| Green Alpha Advisors, LLC | $3 043 550 | 55 804 | 0,09% | Acciones |
| Walleye Trading LLC | $3 005 154 | 55 100 | 0,09% | Opción de compra |
| Caption Management, LLC | $2 999 700 | 55 000 | 0,09% | Opción de compra |
| MetLife Investment Management, LLC | $2 958 413 | 54 243 | 0,09% | Acciones |
| BENJAMIN EDWARDS INC | $2 956 845 | 54 216 | 0,09% | Acciones |
| Quantinno Capital Management LP | $2 869 349 | 52 610 | 0,09% | Acciones |
| Cetera Investment Advisers | $2 856 133 | 52 368 | 0,09% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $2 788 521 | 51 128 | 0,08% | Acciones |
| CITIGROUP INC | $2 781 540 | 51 000 | 0,08% | Opción de compra |
| CITIGROUP INC | $2 781 540 | 51 000 | 0,08% | Opción de venta |
| WOLVERINE ASSET MANAGEMENT LLC | $2 727 000 | 50 000 | 0,08% | Opción de venta |
| OSAIC HOLDINGS, INC. | $2 693 150 | 49 381 | 0,08% | Acciones |
| Privium Fund Management B.V. | $2 452 882 | 44 974 | 0,07% | Acciones |
| CANADA PENSION PLAN INVESTMENT BOARD | $2 394 306 | 43 900 | 0,07% | Acciones |
| TUDOR INVESTMENT CORP ET AL | $2 318 604 | 42 512 | 0,07% | Acciones |
Informantes de la empresa 32 insiders · 12 directivos · 16 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 20 de marzo de 2026 M | 255 501 | 0 | 9 | $-10 756 932 |
| Brendan Smith | Chief Financial Officer | 18 de febrero de 2023 M | 5 072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 11 de marzo de 2021 M | 1 891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 20 de marzo de 2025 M | 10 544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 16 de agosto de 2022 A | 26 797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 29 de mayo de 2026 A | 19 357 | 1 | 2 | $-312 892 |
| James R. Kasinger | General Counsel and Secretary | 29 de mayo de 2026 A | 94 308 | 0 | 5 | $-645 902 |
| Phuong Khanh Morrow | Chief Medical Officer | 13 de octubre de 2023 A | 4 411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 3 de diciembre de 2021 M | 52 364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 16 de enero de 2018 M | 25 204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 15 de junio de 2017 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 24 de octubre de 2016 C | 505 617 | 0 | 0 | $0 |
| Christian Rommel | Consejero | 5 de junio de 2026 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | Consejero | 5 de junio de 2026 A | — | 0 | 0 | $0 |
| Douglas A Treco | Consejero | 5 de junio de 2026 A | — | 0 | 0 | $0 |
| Briggs Morrison | Consejero | 5 de junio de 2026 A | — | 0 | 0 | $0 |
| Katherine A High | Consejero | 5 de junio de 2026 A | — | 0 | 0 | $0 |
| Ali Behbahani | Consejero | 5 de junio de 2026 A | 14 | 0 | 0 | $0 |
| John Greene | Consejero | 5 de junio de 2026 A | 7 000 | 0 | 0 | $0 |
| Simeon George | Consejero | 5 de junio de 2026 A | 1 730 179 | 0 | 0 | $0 |
| Maria Fardis | Consejero | 5 de junio de 2026 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | Consejero | 5 de junio de 2026 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | Consejero | 9 de junio de 2022 A | 148 831 | 0 | 0 | $0 |
| Pablo J Cagnoni | Consejero | 19 de noviembre de 2019 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | Consejero | 18 de diciembre de 2018 S | 1 171 268 | 0 | 0 | $0 |
| Thomas Woiwode | Consejero | 15 de junio de 2018 A | 640 014 | 0 | 0 | $0 |
| Anthony N Coles | Consejero | 31 de mayo de 2017 A | 70 000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | Propietario del 10% | 4 de diciembre de 2017 S | 3 722 534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | Propietario del 10% | 24 de octubre de 2016 C | 744 380 | 0 | 0 | $0 |
| GSK plc | Propietario del 10% | 24 de octubre de 2016 C | 3 220 627 | 0 | 0 | $0 |
| Raju Prasad | — | 7 de agosto de 2026 G | 14 815 | 0 | 10 | $-5 100 841 |
| Rodger Novak | — | 30 de junio de 2021 S | 573 007 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 6 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 presentaciones | 16 de febrero de 2021 | — | Presentación inicial | — | SEC |
| GlaxoSmithKline plc ×5 presentaciones | 10 de julio de 2020 | — | Presentación inicial | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 presentaciones | 4 de febrero de 2020 | — | Presentación inicial | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 presentaciones | 7 de junio de 2019 | — | Presentación inicial | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 presentaciones | 8 de febrero de 2018 | — | Presentación inicial | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 presentaciones | 16 de enero de 2018 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 32 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| GNOM · Global X Funds | 3,85% | 38 191 NS | 31 de mayo de 2026 | N-PORT |
| IDNA · iShares Trust | 1,63% | 62 247 SH | 8 de agosto de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,98% | 97 235 NS | 30 de abril de 2026 | N-PORT |
| IBB · iShares Trust | 0,36% | 658 537 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,35% | 5 248 SH | 8 de agosto de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,28% | 70 696 SH | 8 de agosto de 2026 | Diario |
| IWN · iShares Trust | 0,27% | 752 223 SH | 8 de agosto de 2026 | Diario |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,21% | 104 016 NS | 31 de mayo de 2026 | N-PORT |
| ISCV · iShares Trust | 0,15% | 20 568 SH | 8 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,15% | 2 353 025 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,15% | 536 446 SH | 8 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,15% | 39 589 NS | 30 de abril de 2026 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,10% | 6 636 SH | 8 de agosto de 2026 | Diario |
| ISCB · iShares Trust | 0,07% | 4 136 SH | 8 de agosto de 2026 | Diario |
| SMLF · iShares Trust | 0,07% | 57 970 SH | 8 de agosto de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,06% | 1 106 455 SH | 8 de agosto de 2026 | Diario |
| ESML · iShares Trust | 0,06% | 33 283 SH | 8 de agosto de 2026 | Diario |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,06% | 108 NS | 31 de mayo de 2026 | N-PORT |
| WSML · iShares Trust | 0,04% | 5 486 SH | 8 de agosto de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 13 170 SH | 8 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,04% | 109 974 SH | 8 de agosto de 2026 | Diario |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 1 736 SH | 8 de agosto de 2026 | Diario |
| XT · iShares Trust | 0,03% | 21 837 SH | 8 de agosto de 2026 | Diario |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,03% | 3 509 NS | 31 de mayo de 2026 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 7 774 SH | 8 de agosto de 2026 | Diario |
| ESGV · VANGUARD WORLD FUND | 0,01% | 20 627 SH | 8 de agosto de 2026 | Diario |
| IYY · iShares Trust | 0,01% | 4 231 SH | 8 de agosto de 2026 | Diario |
| ITOT · iShares Trust | 0,01% | 128 511 SH | 8 de agosto de 2026 | Diario |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,01% | 15 609 NS | 31 de mayo de 2026 | N-PORT |
| IWV · iShares Trust | 0,01% | 25 457 SH | 8 de agosto de 2026 | Diario |
| AVSU · AMERICAN CENTURY ETF TRUST | 0,00% | 289 NS | 31 de mayo de 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 75 392 SH | 8 de agosto de 2026 | Diario |